Increff vs Kenvue
Side-by-side comparison of AI visibility scores, market position, and capabilities
Bengaluru inventory management platform founded in 2016; raised $10M+; serves fashion brands across South and Southeast Asia with assortment planning and inventory optimization tools.
About
Increff was founded in 2016 in Bengaluru, India and raised over $10M to build an inventory management and merchandising intelligence platform for fashion, apparel, and lifestyle brands and retailers operating across online and offline channels. The company was founded by former Amazon and McKinsey executives who saw an opportunity to bring data-driven inventory optimization to a market — branded retail in South and Southeast Asia — where most companies still managed inventory through manual processes and gut-feel assortment decisions.\n\nThe Increff platform covers assortment planning, inventory allocation, replenishment optimization, and multi-channel inventory management, with analytics that help merchandising teams understand sell-through rates, size curve performance, and inventory efficiency across their store network and e-commerce channels. The platform's algorithms help brands reduce both excess inventory — a major profitability drain in fashion retail — and stockouts that result in lost sales and markdown pressure.\n\nIncreFF serves fashion, apparel, and lifestyle brands and retailers with significant operations in India and Southeast Asia, and has been expanding its presence in the Middle East and other emerging markets. The company competes against larger WMS and planning vendors like Blue Yonder, as well as regional competitors and in-house solutions, differentiating through its deep fashion industry specialization, cost-effectiveness for mid-sized brands, and focus on markets where most enterprise vendors have thin support and implementation capacity.
Skillman NJ consumer health (NYSE: KVUE) ~$15.5B FY2024 revenue; J&J spinoff May 2023, Tylenol/Band-Aid/Neutrogena/Listerine/Aveeno portfolio, talc litigation exposure competing with Haleon and P&G.
About
Kenvue Inc. is a Skillman, New Jersey-based consumer health company — publicly traded on the New York Stock Exchange (NYSE: KVUE) as an S&P 500 Consumer Staples component — marketing and selling over-the-counter medicines, skin health and beauty products, and essential health products through iconic consumer brands including Tylenol (pain and fever relief), Band-Aid (wound care), Neutrogena (skin care), Johnson's (baby care), Listerine (oral care), Aveeno (skincare), Motrin/Advil (ibuprofen pain relief), Zyrtec (allergy), Nicorette (smoking cessation), Neosporin (antibiotic ointment), and Benadryl through approximately 22,000 employees in 165 countries. Kenvue was separated from Johnson & Johnson through an IPO in May 2023 (the largest US IPO of 2023) and a tax-free distribution of J&J's remaining 89.6% stake to J&J shareholders in August 2023 — creating the world's largest pure-play consumer health company by market capitalization, with J&J retaining no ownership. In fiscal year 2024, Kenvue reported revenues of approximately $15.5 billion, with organic growth facing headwinds from lower cold/cough/flu season severity (Tylenol, Zyrtec, Benadryl volume sensitive to respiratory illness intensity), competitive pressure in skin health (Neutrogena competing with Korean beauty brands, Cerave, and pharmacy private label), and macroeconomic consumer trading down to lower-price alternatives in some markets. CEO Thibaut Mongon leads Kenvue's strategy of investing in the brand superiority of its household name portfolio while improving operational efficiency in the post-spinoff period (implementing Kenvue's own supply chain infrastructure, IT systems, and organizational structure previously shared with J&J).
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.